scispace - formally typeset
M

Masashi Mizuguchi

Researcher at University of Tokyo

Publications -  213
Citations -  6288

Masashi Mizuguchi is an academic researcher from University of Tokyo. The author has contributed to research in topics: Encephalopathy & Rotavirus. The author has an hindex of 38, co-authored 203 publications receiving 5347 citations.

Papers
More filters
Journal ArticleDOI

Acute encephalopathy associated with influenza and other viral infections

TL;DR: Various syndromes of acute encephalopathy are reviewed by classifying them into three major categories, caused by metabolic derangement, which includes Reye‐like syndrome, hemorrhagic shock and encephalitis syndrome, and acute necrotizing encephalopathic syndrome.
Journal ArticleDOI

Acute necrotising encephalopathy of childhood: a new syndrome presenting with multifocal, symmetric brain lesions.

TL;DR: Based on the characteristic combination of clinical and pathological findings, acute necrotising encephalopathy of childhood can be distinguished from previously known encephalopathies, including Reye's syndrome.
Journal ArticleDOI

Epidemiology of acute encephalopathy in Japan, with emphasis on the association of viruses and syndromes.

TL;DR: A research committee supported by the Japanese government conducted a nationwide survey on the epidemiology of acute encephalopathy in Japan using a questionnaire, finding that Mortality was high in ANE and HSES, but was low in AESD, MERS and HHV-6-associated encephalopathic syndromes.
Journal ArticleDOI

Acute necrotizing encephalopathy of childhood: a novel form of acute encephalopathy prevalent in Japan and Taiwan

TL;DR: The clinical, radiological and pathological features of acute necrotizing encephalopathy of childhood, a disease entity established recently, are described and its distinction from clinically similar conditions and from pathologically related conditions, such as the Leigh and Wernicke encephalopathies are discussed.
Journal ArticleDOI

Rapamycin reverses impaired social interaction in mouse models of tuberous sclerosis complex.

TL;DR: It is shown that mammalian target of rapamycin inhibitors may be useful for the pharmacological treatment of autism spectrum disorder associated with tuberous sclerosis complex and other conditions that result from dysregulated mammalian targets ofRapamycin signalling.